Adagene Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapies for the treatment of cancer and other diseases. The company was founded in 2011 and is headquartered in Suzhou, China, with additional offices in the United States and Australia.
Adagene's proprietary technology platform, Dynamic Precision Library (DPL), is a next-generation antibody discovery and engineering platform that enables the rapid and efficient discovery of novel antibodies with high specificity and affinity for their targets. The DPL platform integrates advanced bioinformatics, molecular biology, and protein engineering techniques to identify and optimize antibody candidates for clinical development.
Adagene's lead product candidate, ADG106, is a novel agonistic antibody that targets the checkpoint protein CD137 and is designed to activate the immune system to attack cancer cells. ADG106 is currently being evaluated in a Phase 1 clinical trial for the treatment of advanced solid tumors.
In addition to ADG106, Adagene has a pipeline of antibody-based therapies for the treatment of various types of cancer, including lung cancer, breast cancer, and pancreatic cancer. The company also has programs in development for the treatment of autoimmune diseases and other indications.
Adagene's innovative approach to antibody discovery and engineering has garnered recognition and support from investors and partners. The company has raised significant funding from leading investors, including Hillhouse Capital Group, Qiming Venture Partners, and Sequoia Capital China. Adagene has also entered into collaborations with global pharmaceutical companies, such as Bristol Myers Squibb and I-Mab Biopharma, to develop and commercialize its novel antibody therapies.
With a strong scientific foundation, a growing pipeline of novel antibody-based therapies, and strategic partnerships, Adagene is well-positioned to advance the field of antibody-based therapeutics and improve the lives of patients with cancer and other diseases.
Comments